Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

RegulatoryapprovedPM647PM577aPositive

AI Analysis

Summary

Prime Medicine announced U.S. FDA clearance of an Investigational New Drug Application for PM647 to treat Alpha-1 Antitrypsin Deficiency, with initial clinical data expected in 2027. The clearance demonstrates progress in Prime Medicine's liver-focused therapeutic franchise following regulatory clearances for PM577a.

Outcome Details

U.S. FDA Clearance of Investigational New Drug Application

Importance:6/10

Sentiment:

0.70

FDA clearanceIND approvalalpha-1 antitrypsin deficiencyliver franchisegene therapy

Related Companies

$SHWZ $DRTSW

Read the original article

Published by GlobeNewswire Clinical Studies on September 24, 2026 8:01 PM

Read Original